Introduction Pharmacokinetic outcomes of transporter-mediated drug-drug interactions (TMDDIs) are increasingly being evaluated clinically. The goal of our study was to determine the effects of selective inhibition of multidrug and toxin extrusion protein 1 (MATE1), using famotidine, on the pharmacokinetics and pharmacodynamics of metformin in healthy volunteers. Methods Volunteers received metformin alone or with famotidine in a crossover design. As a positive control, the longitudinal effects of famotidine on the plasma levels of creatinine (an endogenous substrate of MATE1) were quantified in parallel. Conclusions These results suggest that famotidine may improve the bioavailability and enhance the renal clearance of metformin.
Introduction
The multidrug and toxin extrusion protein (MATE) transporters [i.e. MATE1 (SLC47A1) and MATE2 (SLC47A2)] mediate the excretion of endogenous and exogenous compounds into urine and bile, and play important roles in the clinical pharmacokinetics and pharmacodynamics of numerous drugs [1] . Recently, the International Transporter Consortium (ITC) recommended that evaluation of MATE-mediated drug-drug interactions (DDIs) be incorporated into drug development programs. In particular, the ITC recommended that a clinical DDI study should be considered for new molecular entities that (1) are predicted to cause inhibition of MATEs at clinically relevant concentrations, and (2) are identified as MATE substrates and for which renal secretion accounts for at least 25 % of their total elimination. In the first case, for new molecular entities that inhibit MATE1 or MATE2 in in vitro assays, a sensitive substrate for both MATEs, such as metformin, was recommended for use as the victim drug in the clinical study. In the second case, for new drugs that are substrates of MATE1, the ITC recommended the use of a clinically validated MATE probe inhibitor [e.g. greater than tenfold more potent for MATEs compared with organic cation transporter 2 (OCT2)] such as cimetidine or pyrimethamine in the clinical study [1] . However, at clinical concentrations, cimetidine and pyrimethamine inhibit both MATE1 and MATE2. Therefore, the effect of a selective MATE1 inhibitor (greater than tenfold more potent for MATE1 compared with MATE2 and OCT2) on pharmacokinetics, particularly renal drug secretion, is not known.
In the kidney, MATE1 and MATE2 are highly expressed on the apical membrane of the renal epithelium, and have somewhat overlapping substrate specificities (e.g. metformin, procainamide and thiamine, but not oxaliplatin or cephalexin) [2] [3] [4] [5] [6] [7] [8] . Interestingly, MATE1 transporters are ubiquitously expressed in both the kidney proximal and distal tubules, as well as in intestine tissue and on the canalicular membranes of hepatocytes, whereas MATE2 transporters are localized specifically in the kidney proximal tubules in humans and are absent in mice [8] [9] [10] . Creatinine is an endogenous metabolite eliminated unchanged in the urine by glomerular filtration and tubular secretion (10-40 %) [11] . While transporter-mediated tubular secretion of creatinine is reported to involve OCT2/ 3, organic anion transporter 2 (OAT2, uptake into the renal cell) and MATE1/2 (subsequent efflux from the renal cell into the urine) [12, 13] , inhibition of the efflux transporter MATE1, in particular, has been suggested as the mechanism for the decrease in renal clearance of creatinine observed in multiple clinical studies [12] .
Determination of metformin pharmacokinetics is currently the gold standard for investigating clinical transporter-mediated DDIs (TMDDIs) involving renal OCT inhibition. Metformin, an antihyperglycemic agent, is commonly recommended as first-line pharmacotherapy for treating type 2 diabetes mellitus (T2DM). A small cationic drug at physiologic pH ([99 % ionized in blood and urine), metformin interacts with OCTs and MATEs to traverse membranes for access to target tissues, such as the liver, and for elimination from the body (i.e. through the kidney) [14, 15] . The importance of MATEs in the clinical pharmacokinetics of metformin has been clearly documented; however, MATE1-specific evidence in humans is currently limited to genetic studies [16] [17] [18] [19] [20] [21] [22] . Evidence in rodents shows that deletion of the murine MATE1 gene, [Mate1 (-/-)] can significantly reduce metformin urinary excretion and significantly increase metformin plasma, kidney, and liver concentrations compared with wild-type mice (Mate1 [?/?]) [16, 17] . Since mice do not express the MATE2 transporter, it is not surprising that nonselective chemical MATE inhibitors (e.g. cimetidine and pyrimethamine) effectively mimic rodent knockout strains by reducing metformin renal clearance and increasing plasma exposure in mice, as well as in healthy human volunteers [23] [24] [25] . Although clinically validated selective MATE1 inhibitors are not currently available, genetic studies investigating single nucleotide polymorphisms (SNPs) in the human MATE1 gene provide insight regarding the selective importance of MATE1 in humans [18] [19] [20] [21] [22] . In particular, a SNP located in the intronic region of the MATE1 gene (G[A, SNP rs2289669) is associated with better response (greater glycated hemoglobin (A1C) reduction) to metformin therapy in T2DM patients [18] [19] [20] [21] , although the mechanism for this effect is unknown. Likewise, a common mutation in the promoter region of the MATE1 gene (T[C, SNP rs2252281) is associated with improved response to metformin in T2DM patients (greater A1C reduction), as well as in healthy volunteers (greater glucose-lowering effect) [22] . Functional studies demonstrate that the T[C mutation in the promoter region of the MATE1 gene alters the binding affinity for MATE1 transcription factors (i.e. activator AP-1 and repressor AP2rep), which reduces MATE1 messenger RNA (mRNA) expression levels in in vitro assays [26] . Although an effect of genetic variants in MATE1 on human pharmacokinetics has not been observed, these studies suggest that MATE1 plays an important role in the distribution of metformin to target tissues, as well as in the glycemic response to metformin.
The goal of this study was to determine the effect of selective MATE1 inhibition on the pharmacokinetics and pharmacodynamics of metformin, as well as on creatinine levels as a positive control, in healthy volunteers. Recently, in a large prescription drug-screening study, Wittwer et al. [27] identified 84 MATE1 inhibitors, including four compounds predicted to selectively inhibit MATE1 at clinical concentrations (i.e. famotidine, imatinib, indinavir, and ritonavir). For this study, we selected to evaluate famotidine as an in vitro and in vivo inhibitor of metformin transport by MATE1 in human cells and healthy volunteers, respectively. Famotidine, an H2-receptor antagonist used to reduce gastric acid secretion, is marginally bound to plasma proteins (approximately 20 %) and is eliminated by renal (65-70 %) and metabolic (30-35 %) routes [28] [29] [30] [31] [32] . We hypothesized that selective inhibition of MATE1 by famotidine would phenocopy the effects of the reduced expression MATE1 promoter variant (T[C, SNP rs2252281), resulting in improved glycemic response to metformin. In addition, we hypothesized that in the presence of a selective MATE1 inhibitor, the renal clearance of metformin and creatinine would decrease.
Methods

Clinical Study Procedures
Healthy volunteers were recruited as described in the electronic supplementary material (ESM) . In this open-label, two-phase, crossover study, an equal number of volunteers completed the metformin alone followed by metformin plus famotidine treatment sequence (n = 6) as those who completed the same treatments but in reverse order, i.e. metformin plus famotidine followed by metformin alone (n = 6) (see clinical study design, Fig. 1 ). The interval between treatment phases was set to a minimum of 7 days to allow for complete elimination of the study drugs. Study day procedures are described below.
Metformin-Alone Phase
Volunteers reported to the Clinical Research Center (CRC) at San Francisco General Hospital (SFGH) after a 3-day carbohydrate-controlled diet (200-250 g/day) and an overnight fast (10 h), where they remained for the duration of the visit (48 h). Vital signs were obtained, inclusion/ exclusion criteria were confirmed, and a 3-h oral glucose tolerance test (OGTT; 75 g) was performed in the morning of day 1. Subjects were administered a 1000 mg immediate-release tablet (IRT) of metformin in the evening of day 1, followed by an 850 mg IRT 12 h later on day 2. On day 2, after fasting (10 h), a second OGTT was administered 2 h after the second dose of metformin (Fig. 1b) . A normal meal schedule (standardized carbohydrate-controlled meal) was resumed on both study days after completion of the OGTT. For 12 h following the second dose of metformin, volunteers were asked to drink 8 oz of water every 2 h to maintain urine flow and pH. A series of venous blood Fig. 1 Design to study the effects of famotidine, a MATE1-selective inhibitor, on metformin pharmacokinetics and pharmacodynamics in healthy volunteers. a Volunteers in Arm 1 received metformin alone (1850 mg in two divided doses), followed by a 7-day washout, then metformin ? famotidine (1850 mg in two-divided doses and 1000 mg in six divided doses, respectively) during two separate study treatment visits. Volunteers in Arm 2 received the same treatments but in reverse order, i.e. metformin ? famotidine, washout, then metformin alone. b During each 48-h treatment visit, OGTTs were performed after a 10-h overnight fast on day 1 and day 2. Black bars indicate the time of drug administration. MATE1 multidrug and toxin extrusion protein 1, OGTTs oral glucose tolerance tests samples were drawn at 0, 0.5, 1, and 2 h after the first metformin dose, and 0, 0.5, 1, 2, 2.25, 2.5, 2.75, 3, 3.5, 4, 5, 6, 8, 10, 12 , and 24 h after the second metformin dose for pharmacokinetic analysis of metformin. Blood samples were collected at 0, 15, 30, 45, 60, 90, 120, and 180 min after each glucose administration for pharmacodynamic analysis (glucose concentrations). Each blood sample was collected into heparinized tubes and kept on ice until centrifugation (3000 rpm for 10 min at 4°C). Urine samples were collected at the following time intervals: predose, 0-12 h after the first metformin dose, and 0-2, 2-4, 4-6, 6-8, 8-12, and 12-24 h after the second metformin dose. Urine volume and pH were recorded for each interval. Aliquots of all plasma and urine specimens were stored at -80°C pending bioanalysis.
Metformin Plus Famotidine Phase
Procedures for the metformin plus famotidine phase were repeated as described above, with the addition of six oral doses of famotidine (1000 mg in total) administered over the course of the 48-h visit. A single dose of famotidine (200 mg) was administered 1 h prior to the OGTT on day 1. Multiple doses of famotidine (160 mg each) were administered at 4-hourly intervals beginning 9 h before the second dose of metformin (see study design, Fig. 1b ). Eight additional blood draws (5 mL each) were taken at 0, 0.5, 1, 1.5, 2, 2.5, 3, and 4 h on day 1 for single-dose pharmacokinetic analysis of famotidine.
Analytical Methods
Metformin and famotidine concentrations in plasma and urine were concomitantly quantified using liquid chromatography-tandem mass spectrometry (LC-MS/MS). The assay included modifications from a previously reported method [22, 33] , as follows: each aliquot of clinical sample (plasma or urine) was mixed with three volumes of acetonitrile containing internal standards (i.e. metformin-d6 for metformin, and phenformin for famotidine). The mobile phase consisted of 80 % acetonitrile, 20 % doubledistilled water, 0.1 % 10 mM ammonium formate, and 0.02 % 5 mM formic acid (v/v). The assay was validated, and the range of the calibration curve in plasma was 5-2000, and 40-4000 ng/mL in urine, for both famotidine and metformin. Both the intraday and interday assay coefficients of variation were less than 10 % for both analytes. Glucose concentrations in plasma, and creatinine concentrations in plasma and urine, were determined by the Clinical Laboratory Improvement Amendments (CLIA)-certified Clinical Laboratory at SFGH. For in vitro methodology, see the ESM.
Clinical Pharmacokinetics
The pharmacokinetic parameters of metformin (0-24 h after the second dose, 1850 mg in total) and famotidine (0-4h and 12 h after a single 200 mg dose) were evaluated using noncompartmental analysis, as previously described (Phoenix WinNonlin, 6.3.0; Pharsight Corporation, a Certara Company, St. Louis, MO, USA) [33] . Participants and treatment periods with missing or inaccurate urine volumes were excluded from the statistical analysis. Since inhibition of MATE1 is known to alter creatinine concentrations, and famotidine does not affect glomerular filtration [34, 35] , the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation was used to calculate creatinine clearance (CL CR ) and estimate glomerular filtration rate (GFR) [36] . Metformin renal secretion clearance (CL RS ) was calculated based on the estimated GFR using the equation CL RS = CL R -f u ÁGFR, where f u is the fraction of unbound metformin in plasma. Metformin total renal clearance (CL R ) was calculated using the total amount of metformin excreted in urine (A e36 ) divided by the total area under the curve (AUC 36 ) after two doses. The plasma AUC 36 was determined by a population approach using population pharmacokinetic parameters from a model previously developed in healthy volunteers under similar study conditions, together with integration techniques in NONMEM [37] . Bioavailability was calculated as the total amount of metformin excreted in the urine estimated to infinity divided by the total dose of metformin (1850 mg), assuming that metformin is eliminated entirely by the kidney (f e = 1) [38] . For a description of the pharmacometric modeling and simulation methodologies for famotidine and creatinine, see the ESM.
Statistical Analysis
The size of the study population (n = 12) was calculated to allow detection of a true difference of more than 30 % in AUC 3 of glucose, with a power of 80 % and a significance level of 5 %. Data are presented as mean ± standard error of the mean (SEM) unless otherwise specified. Paired nonparametric Student's t tests were used to analyze the differences in metformin pharmacokinetic and pharmacodynamic parameters during metformin alone versus metformin plus famotidine, as well as for between genotypes, using GraphPad Prism 5.0 (GraphPad Software Inc., San Diego, CA, USA). Geometric mean ratios (GMRs) and 90 % confidence intervals (CI) about the GMRs were calculated using Stata 12.1 (StataCorp LP, College Station, TX, USA) to estimate clinically relevant differences in metformin pharmacokinetic parameters with standard bioequivalence boundaries of 80-125 %.
Results
Famotidine In Vitro Assays
The inhibitory effect of famotidine on 14 C-labeled metformin transport was evaluated in HEK293 cells stably overexpressing OCTs (ESM Fig. 1 ). The mean (95 % CI) concentration of drug producing 50 % inhibition (IC 50 ) values for famotidine against metformin transport were 0.25 lM (0.20-0.32 lM), 2.5 lM (1.5-4.0 lM), 19 lM (10-35 lM), and 66 lM (48-90 lM) in hMATE1, hMATE2, hOCT1, and hOCT2 cells, respectively. In this study, the term 'selective' MATE1 inhibitor refers to the selectivity of famotidine for MATE1 in comparison to these transporters.
Healthy Volunteers
A total of 14 healthy male and female volunteers were recruited from the Studies of Pharmacogenetics in Ethnically Diverse Populations (SOPHIE) cohort. Two volunteers experienced nausea after metformin administration and voluntarily withdrew from the study (see study design, Fig. 1 ). Twelve subjects, all of European ancestry, completed both phases of the study and were included in the pharmacokinetic and pharmacodynamic analyses. Demographic characteristics are found in Table 1 . 
, and 0.015, respectively, which indicates that famotidine reached plasma levels predictive of highly selective inhibition of metformin transport by MATE1 in the kidney, without appreciably inhibiting metformin transport by OCT1 or OCT2 and with only minimal inhibition of MATE2 (ESM Fig. 2) . Therefore, to our knowledge, famotidine is the first clinically validated highly selective MATE1 inhibitor using oral doses of 160-200 mg. For population pharmacokinetic parameter estimates of famotidine, see the ESM.
Clinical Pharmacokinetics of Metformin
Mean metformin plasma concentration-time curves during metformin alone and during metformin with famotidine are shown in Fig. 2a . The pharmacokinetic parameters of metformin are comparable to previous reports in healthy volunteers [22, 33, 39, 40] . Famotidine did not significantly affect the maximum concentration in plasma (C max ), AUC, or total clearance (CL/F) of metformin (Table 2) ; however, it did increase the cumulative amount of metformin excreted in the urine at the total time of 36 h and at the time estimated to infinity (p \ 0.005) (Fig. 2b) . On average, famotidine significantly increased the estimated metformin bioavailability [F, cumulative amount of unchanged drug excreted in urine from time zero to infinity (A e? )/dose] by 24 % (Fig. 2c) Fig. 2d; Table 2 ). Interestingly, an increase in metformin fractional renal clearance 0-12 h postmetformin administration was observed (ESM Fig. 3 ). Although no difference in urine flow rate between treatment phases was documented, famotidine significantly decreased the urine pH between 0 and 12 h after metformin administration (p \ 0.005) ( Table 2 ).
Clinical Pharmacodynamics of Metformin
Healthy volunteers (n = 12) underwent 3-h OGTTs to evaluate the effect of famotidine on the glucose-lowering response to metformin. Baseline plasma glucose concentrations (before glucose ingestion) were similar during each treatment phase. Glucose AUCs before and after metformin therapy alone, and after metformin-famotidine co-therapy, as a comparison of metformin glucose-lowering response (Fig. 3) . Famotidine alone produced no significant effect on glucose AUC (data not shown). Thus, the ability of metformin to reduce the AUC of glucose during the first 30 min after glucose ingestion was significantly improved by famotidine; however, the improvement in glucose AUC reduction was not sustained beyond 30 min.
Discussion
In this study, using famotidine, we determined the effect of selective MATE1 inhibition on the pharmacokinetics and pharmacodynamics of metformin and creatinine in healthy volunteers. Our major findings were (1) famotidine increases the estimated bioavailability (A e? /dose) of metformin; (2) selective MATE1 inhibition does not result in reduced renal clearance or net clearance by secretion of metformin; (3) selective MATE1 inhibition is sufficient to alter creatinine levels in opposing directions; (4) The effects of famotidine on metformin pharmacokinetics differ from those of traditional nonselective MATE1/MATE2 inhibitors; and (5) famotidine transiently improves the glucose-lowering effects of metformin. The data supporting these findings, and their implications to understanding the mechanisms of metformin pharmacokinetics and pharmacodynamics, are discussed below. Previous studies demonstrate that the rate of metformin elimination is much faster than its rate of absorption, which indicates flip-flop kinetics; that is, that the terminal linear portion of the plasma concentration-time curve actually reflects absorption instead of elimination [38, 41] . In this study, although the C max and AUC of metformin did not significantly increase with famotidine co-therapy, metformin concentrations at later time points (i.e. 12 and 24 h post-metformin administration) were significantly higher. Additionally, the time to C max (i.e. T max ) decreased 20 % [GMR (90 % CI) 0.80 (0.60-1.06)] with famotidine (p \ 0.01); however, the terminal half-life did not significantly change (Table 2) . Importantly, the bioavailability and cumulative amount of metformin excreted in the urine significantly increased following famotidine coadministration (Fig. 2b, c) . Since metformin does not undergo appreciable metabolism or biliary excretion, interactions of famotidine with metformin transporters involved in its absorption may explain the apparent increase in bioavailability [42] [43] [44] [45] . MATE1 is expressed in human intestine and liver, and was localized to cell membrane as well as intracellular organelles that may play a role in metformin transport [2-7, 9, 10] . In addition, tissue distribution studies in mice treated with the MATE inhibitor pyrimethamine indicate that liver and kidney levels of metformin are significantly increased, even without a change in plasma concentrations [16, 17, 24, 46, 47] . These reports, together with our results, suggest that famotidine may increase the rate and extent of metformin absorption or alter hepatic distribution, resulting in less intestinal elimination and improved absorption. Moreover, famotidine has a b c d Fig. 2 The effect of famotidine on metformin pharmacokinetics in healthy volunteers (n = 12). a The mean metformin plasma concentration-time curves from 0-24 h following metformin administration alone (1850 mg in total) (closed circles) and during coadministration with famotidine (1000 mg over 48 h) in healthy volunteers (n = 12).
The asterisks indicate significant differences; p \ 0.01. b Cumulative urinary excretion of metformin after two doses of metformin alone (1850 mg in total) (solid circles) or during co-therapy with famotidine (open circles). Values are expressed as mean ± SEM. c Estimated metformin bioavailability (A e? /dose). d Metformin CL R for 36 h, computed using NONMEM, during metformin treatment alone (square) and during coadministration with famotidine (triangle). SEM standard error of the mean, A e? cumulative amount of unchanged drug excreted in urine from time zero to infinity, CL R renal clearance Blood and urine collection was complete for all participants, except in one individual with one incomplete urine collection (0-2 h after metformin therapy during the metformin plus famotidine phase). The individual with the incomplete urine collection was excluded when calculating A e , F and CL R . Total amount of metformin excreted in the urine through time infinity with and without famotidine was estimated by fitting the mean amount excreted in the urine versus time to a Hill equation where A e? represented the plateau value. Data are expressed as mean ± SEM unless stated otherwise. P values of less than 0.05 are considered significant GMR geometric mean ratio, CI confidence interval, C max maximal plasma concentration, T max time to the maximal plasma concentration, T 1/2 plasma terminal elimination half-life, CL/F apparent systemic clearance, V/F apparent volume of distribution, AUC 24/36/? area under the metformin plasma concentration-time curve from 12 to 36 or 0 to 36 h or 0 to infinity, respectively, where 0 is the time of first metformin dose administration, F estimated bioavailability, A e36/? amount of metformin excreted in the urine from 0 to 36 h after initial dose or to infinity, respectively, CL R,met,36 metformin renal clearance from 0 to 36 h, CL RS,met,36 metformin secretory clearance from 0 to 36 h, calculated as CL RS = CL R -f u . GFR where CL R , f u , and GFR are metformin renal clearance, fraction of unbound metformin in plasma, and glomerular filtration rate, respectively, assuming negligible metformin reabsorption. The value of f u was set at 1, and GFR was calculated using the CKD-EPI (2009) equation, without adjustment for body surface area to express GFR in mL/min (http://www.kidney.org/professionals/KDOQI/gfr_calculator), AUCglu ,0.5/3 area under the glucose blood concentration-time curve from 0 to 0.5 or 3 h, respectively, where 0 is the time of glucose administration, CL R,creat,0/12/36/48 creatinine renal clearance at time 0,12, 36 or 48 h after the first famotidine dose administration, respectively a Dose refers to metformin-free base (1332 mg) clear effects in increasing gastric pH, which would result in a greater fraction of the drug in the unionized state, facilitating passive absorption of the drug [31] . Further studies are clearly needed to determine the mechanisms by which famotidine enhances the estimated bioavailability of metformin. Famotidine did not reduce metformin renal clearance as we had hypothesized. Instead, we observed increased metformin renal clearance and renal clearance by secretion during famotidine coadministration after 1850 mg metformin in total (Fig. 2d) . The famotidine-induced increases in both metformin absorption and renal clearance likely had opposing effects, which resulted in no change in metformin plasma exposure (C max or AUC) and no change in metformin clearance (CL/F) ( Table 2) . These results differ from previous findings with the nonselective MATE inhibitors pyrimethamine and cimetidine. In particular, administration of pyrimethamine or cimetidine result in reduced renal clearance and secretory clearance of MATE substrates, including metformin [23, 25, 40, [47] [48] [49] [50] .
Several possible mechanisms may explain the differences between our results with famotidine versus those obtained previously with pyrimethamine and cimetidine.
First, it is possible that the drug simply did not interact with MATE1 during our study, even though it achieved four times higher plasma levels compared with its IC 50 for inhibition of MATE1. Perhaps famotidine concentrations in the vicinity of the transporter (i.e. intracellularly on the apical surface of the renal tubule) may not have been sufficiently high to inhibit MATE1. However, famotidine was determined to be an unequivocal substrate of the transporters MATE1, MATE2, OCT1, and OCT2 in overexpressing cell lines (ESM Fig. 4 ) with renal clearance of 290 ± 32 mL/min, indicating some tubular secretion. Therefore, unbound concentrations of famotidine in the proximal tubule would be expected to be similar to, or even higher than, those in the plasma. Moreover, our data suggest that famotidine did inhibit MATE1. That is, in this study, creatinine concentrations were significantly altered in a manner that is consistent with previous reports of drugs that are potent inhibitors of MATE1 [12, 51] ; urinary CL CR was significantly decreased (Table 1 ) and creatinine concentrations in plasma were significantly higher 12 h after famotidine (200 mg) administration alone compared with pre-famotidine concentrations, as well as compared with matched controls in the absence of famotidine at 12 and 36 h (Fig. 4) . A model was developed to quantify the impact of famotidine on creatinine plasma levels in healthy volunteers while separating out diurnal rhythms in the data (see the ESM, as well as ESM Figs. 5 and 6, and ESM Tables 3, 4). The model described the data well, both for the mean curve and the variability between patients, and the effect of famotidine on creatinine turnover could be quantified with good precision, and proved to be significant (p \ 0.001). It is possible that MATE1 may be a more sensitive transporter of creatinine than metformin, which would need to be determined experimentally; however, our data suggest that famotidine did inhibit MATE1 but did not reduce metformin secretory clearance. The second explanation for the apparent lack of significant reduction of metformin renal clearance, despite alteration in creatinine concentrations, is that metformin renal clearance may be blood flow limited [52] , whereas CL CR is less sensitive to changes in renal blood flow. It is possible that famotidine may have increased renal blood blow in our study, resulting in enhanced metformin renal clearance, although to our knowledge changes in renal hemodynamics with famotidine have not been described. Third, selective MATE1 inhibition may not be sufficient to cause a significantly observable reduction in metformin secretory clearance. That is, unlike creatinine, for metformin, nonselective inhibition of both apical transporters MATE1 and MATE2 may be required. Lastly, inhibition of basolateral transporters (e.g. OCT2) may be more important to metformin pharmacokinetics than apical membrane transporters (e.g. MATEs). Famotidine inhibition of metformin transport is Fig. 1) , whereas cimetidine appears to be a considerably more potent inhibitor of OCT2 [53] . Thus, cimetidine may be a particularly nonselective inhibitor of metformin renal secretory transporters, OCT2, MATE1, and MATE2, compared with famotidine, which is highly selective for MATE1.
The increase in total metformin renal clearance and the trend towards an increased fractional renal secretory clearance of metformin are difficult to explain. It is possible that famotidine inhibits transporter-mediated reabsorption of metformin, which may be mediated through MATE1 or another transporter. For example, famotidine was found to be a potent inhibitor of metformin transport by the plasma membrane monoamine transporter (PMAT, SLC29A4), which has been implicated in facilitating reabsorption of organic cations in the kidney [54] (ESM Fig. 7) . Furthermore, the decrease in urinary pH associated with famotidine administration may have resulted in altered proton-dependent transport. Although speculative, it is possible that famotidine increased metformin renal clearance by decreasing its rate of passive reabsorption in renal tubule. Alternatively, famotidine may have inhibited an as yet unidentified transporter involved in metformin reabsorption in the kidney. Finally, as noted, famotidine may have affected renal blood flow. This result clearly needs further study.
In terms of pharmacodynamics, the effects of famotidine on metformin-induced decreases in OGTT were in the direction that we hypothesized. That is, we observed a significant effect of famotidine in enhancing metformin's response to OGTT in the first 30 min, when famotidine concentrations were the highest. These results are consistent with results obtained previously for the reduced function variant of MATE1 (rs2252281) [22] . Inhibition of MATE1 efflux would result in higher metformin concentrations in the liver and kidney, as well as improved efficacy. However, in this study the effects were small and cannot be extrapolated to diabetic patients.
Conclusions
This study demonstrated that famotidine, a selective inhibitor of MATE1, significantly increases the estimated bioavailability of metformin and produces a transient increase in the pharmacologic response to metformin. Rather than a significant reduction in metformin secretory clearance, we observed an enhanced renal clearance of metformin with famotidine, which is in contrast to nonselective MATE inhibitors [23, 25, 40] that reduce metformin renal clearance. Taken together, the study suggests that improved bioavailability of metformin, as well as enhanced renal clearance, can be obtained with famotidine. Our studies highlight the importance of conducting clinical drug-drug interaction studies because findings may differ from predictions based on in vitro and animal studies. 
